Manhattan Research Releases Top Pharma Brand Product Sites by Consumer Satisfaction

Manhattan ResearchLantus (Sanofi-Aventis), Advair (GlaxoSmithKline), and Singulair (Merck) are the top pharmaceutical brand sites in terms of consumer visitor satisfaction, according to pharmaceutical and healthcare market research company Manhattan Research. The findings are from ePharma Consumer® v8.0, the company's latest study and strategic advisory service focused on how consumers find and use pharmaceutical resources online.

Other top brand sites leading in consumer satisfaction include Abilify (Bristol-Myers Squibb), Caduet (Pfizer), Januvia (Merck), Mirena (Bayer), Nexium/purplepill.com (AstraZeneca), Prevacid (Takeda), and Protonix (Wyeth).

ePharma Consumer® v8.0 tracks consumer interaction with more than 250 branded and unbranded pharmaceutical sites, including in-depth data on the effect of DTC advertising, visitation, site search rationales, desired site tools and features, and actions taken off-site.

"Pharmaceutical marketing is rapidly evolving, and brand teams and agencies are looking beyond number of eyeballs to the site when evaluating their digital strategy. To truly understand online performance, marketers are focusing more on metrics such as engagement, action steps, satisfaction and of course conversions," said Mark Bard, president of Manhattan Research. "While driving visitors to sites is critical, engaging and retaining them will provide the most strategic value to the brand."

Complimentary Webinar - Monday, February 9, 2009
ePharma Consumer® v8.0: The Future of DTC Marketing

Manhattan Research President Mark Bard will preview the latest ePharma Consumer® data and trends for pharmaceutical marketers and agencies to make better-informed consumer marketing strategies. Mark will give insight into topics such as where and how consumers search for pharma info online; organic and paid search for pharma information; social networking and Web 2.0 applications; the corporate and product site landscape; and the role of a patient's condition in online behavior.

Session 1: Monday, February 9, 11:00 AM EST
Register here: https://www2.gotomeeting.com/register/512733945

Session 2: Monday, February 9, 3:00 PM EST
Register here: https://www2.gotomeeting.com/register/858561016

For assistance in signing up, please email your time preference to This email address is being protected from spambots. You need JavaScript enabled to view it. or call 212-255-7799.

About ePharma Consumer® v8.0
ePharma Consumer® v8.0 was conducted via online survey in Q4 2008 among 6,566 adults (age 18+). The study is focused on consumers online for pharmaceutical information. For additional product and subscription information, please visit http://www.manhattanresearch.com/products/Strategic_Advisory/ePC/

Some of the product sites covered in ePharma Consumer® include Abilify, Aciphex, Actonel, Advair, Ambien/Ambien CR, Aranesp, Aricept, Boniva, Botox, Caduet, Chantix, Cialis, Concerta, Crestor, Cymbalta, Depakote, Depo-Provera, Detrol LA, Effexor XR, Enbrel, Flomax, Flonase, Flovent, Fosamax, Gardasil, Humira, Imitrex, Lamisil, Lantus, Lexapro, Levitra, Lipitor, Lunesta, Nasacort, Nasonex, Neulasta, Neurontin, Nexium, Norvasc, NuvaRing, Ortho Evra, Ortho Tri-Cyclen Lo, Paxil, Plavix, Pravachol, Prevacid, Protonix, Provigil, Pulmicort, , Restasis, Risperdal, Rozerem, Seasonale, Seroquel, Singulair, Strattera, Tamiflu, Topamax, Toprol XL, TriCor, Valtrex, Viagra, Vytorin, Wellbutrin XL, Yasmin, Yaz, Zocor, Zoloft, Zomig, and Zyprexa.

About Manhattan Research
Manhattan Research, a Decision Resources, Inc. company, is a leading market research and advisory services firm for global pharmaceutical and healthcare companies. For more information, visit http://www.manhattanresearch.com.

About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at http://www.decisionresourcesinc.com.

Most Popular Now

Johnson & Johnson announces advance purchase a…

Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE: JNJ) (the Company), has entered into an agreement with the African Vacci...

Pfizer and BioNTech confirm high efficacy and no s…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced updated topline results from analysis of 927 confirmed symptomatic cases of COVID-19 observed in their pi...

Pfizer-BioNTech announce positive topline results …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that, in a Phase 3 trial in adolescents 12 to 15 years of age with or without prior evidence of SAR...

GSK to support manufacture of Novavax' COVID-19 va…

GSK has reached an agreement in principle with Novavax and the UK Government Vaccines Taskforce to support manufacturing of up to 60 million doses of Novavax' COVID-19 va...

Valneva reports positive Phase 1/2 data for its in…

Valneva SE, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical n...

Clinical trial completion rates decline during COV…

Social distancing and lockdowns may have reduced the spread of COVID-19, but researchers from Penn State College of Medicine also report those actions may have affected c...

BioNTech provides update on vaccine production sta…

BioNTech SE today announced that the European Medicines Agency (EMA) approved the manufacturing of the COVID-19 vaccine drug product at the facility in Marburg. As part o...

COVID-19 convalescent plasma with greater antibody…

Convalescent plasma, the use of survivors' antibodies transfused into sick COVID-19 patients is safe and significantly improves clinical outcomes when using high levels o...

Pfizer and BioNTech request regulatory agencies ex…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today requested amendments to the U.S. Emergency Use Authorization (EUA) of the Pfizer-BioNTech vaccine (BNT162b2) ...

COVID-19 causes 'unexpected' cellular response in …

New insights into the immune response to SARS-CoV-2 infections could bring better treatments for COVID-19 cases. An international team of researchers unexpectedly foun...

Study identifies possible COVID-19 drugs - includi…

A team led by scientists in the Perelman School of Medicine at the University of Pennsylvania has identified nine potential new COVID-19 treatments, including three that ...

Undetected coronavirus variant was in at least 15 …

A highly contagious SARS-CoV-2 variant was unknowingly spreading for months in the United States by October 2020, according to a new study from researchers with The Unive...